Home > Insider Trading > Filing (0001209191-14-015475)

Filing Details

Accession Number:: 0001209191-14-015475
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2014-02-28 20:10:37
Reporting Period:: 2014-02-26

Filing Date:: 2014-02-28
Accepted Time:: 2014-02-28 20:10:37
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
786947	Acura Pharmaceuticals Inc	ACUR	Pharmaceutical Preparations (2834)	110853640

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1034486	P L Iii Partners Galen	C/O Galen Management, L.l.c. 680 Washington Blvd. Stamford CT 06901	No	No	Yes	No
1034574	P L Iii International Partners Galen	C/O Galen Management, L.l.c. 680 Washington Blvd. Stamford CT 06901	No	No	Yes	No
1056642	Galen Employee Fund Iii Lp	C/O Galen Management L.l.c. 680 Washington Blvd. Stamford CT 06901	No	No	Yes	No
1056643	Claudius Llc	C/O Galen Management, L.l.c. 680 Washington Blvd. Stamford CT 06901	No	No	Yes	No
1421162	Galen Management, Llc	680 Washington Blvd. Stamford CT 06901	No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2014-02-26	6,301	$1.95	11,476,078	No	4	S	Indirect	See FN
Common Stock	Disposition	2014-02-26	5,000	$1.95	11,471,078	No	4	S	Indirect	See FN
Common Stock	Disposition	2014-02-27	192,479	$2.04	11,278,598	No	4	S	Indirect	See FN
Common Stock	Disposition	2014-02-28	147,480	$2.01	11,131,118	No	4	S	Indirect	See FN

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	See FN
No	4	S	Indirect	See FN
No	4	S	Indirect	See FN
No	4	S	Indirect	See FN

Footnotes

The shares were sold as follows: 5,756 by Galen Partners III, L.P. ("Galen III"), 521 by Galen Partners International III, L.P. ("Galen International") and 24 by Galen Employee Fund III, L.P. ("Employee Fund").
The shares were sold at prices between $1.95 and $1.96. The Reporting Entities will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
The shares are held as follows: 10,487,099 by Galen III, 945,782 by Galen International and 43,198 by Employee Fund. Claudius, L.L.C. serves as the sole General Partner of Galen III and Galen International and has sole voting and investment control over the shares held by such funds and may be deemed to beneficially own the shares held by such funds. Galen Management, L.L.C. serves as the sole General Partner of Employee Fund and has sole voting and investment control over the shares held by Employee Fund and may be deemed to beneficially own the shares held by Employee Fund. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein, except to the extent of its respective pecuniary interest therein.
The shares were sold as follows: 4,568 by Galen III, 413 by Galen International and 19 by Employee Fund.
The shares are held as follows: 10,482,531 by Galen III, 945,369 by Galen International and 43,179 by Employee Fund. Claudius, L.L.C. serves as the sole General Partner of Galen III and Galen International and has sole voting and investment control over the shares held by such funds and may be deemed to beneficially own the shares held by such funds. Galen Management, L.L.C. serves as the sole General Partner of Employee Fund and has sole voting and investment control over the shares held by Employee Fund and may be deemed to beneficially own the shares held by Employee Fund. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein, except to the extent of its respective pecuniary interest therein.
The shares were sold as follows: 175,841 by Galen III, 15,916 by Galen International and 722 by Employee Fund.
The shares were sold at prices between $2.042 and $2.11. The Reporting Entities will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
The shares are held as follows: 10,306,690 by Galen III, 929,453 by Galen International and 42,457 by Employee Fund. Claudius, L.L.C. serves as the sole General Partner of Galen III and Galen International and has sole voting and investment control over the shares held by such funds and may be deemed to beneficially own the shares held by such funds. Galen Management, L.L.C. serves as the sole General Partner of Employee Fund and has sole voting and investment control over the shares held by Employee Fund and may be deemed to beneficially own the shares held by Employee Fund. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein, except to the extent of its respective pecuniary interest therein.
The shares were sold as follows: 134,731 by Galen III, 12,194 by Galen International and 554 by Employee Fund.
The shares were sold at prices between $2.00 and $2.07. The Reporting Entities will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
The shares are held as follows: 10,171,959 by Galen III, 917,259 by Galen International and 41,903 by Employee Fund. Claudius, L.L.C. serves as the sole General Partner of Galen III and Galen International and has sole voting and investment control over the shares held by such funds and may be deemed to beneficially own the shares held by such funds. Galen Management, L.L.C. serves as the sole General Partner of Employee Fund and has sole voting and investment control over the shares held by Employee Fund and may be deemed to beneficially own the shares held by Employee Fund. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein, except to the extent of its respective pecuniary interest therein.